Rationale: The role of MUC5B mucin expression in IPF pathogenesis is unknown.
Bleomycin-exposed rodent models do not exhibit sustained fibrosis or airway remodeling …

The gain-of-function minor allele of the MUC5B (mucin 5B, oligomeric mucus/gel-forming)
promoter (rs35705950) is the strongest risk factor for idiopathic pulmonary fibrosis (IPF), a …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with
underlying mechanisms that have been primarily investigated in mice after intratracheal …

Idiopathic pulmonary fibrosis (IPF) is an incurable genetic disease that affects 5 million
people worldwide. The gain-of-function MUC5B promoter variant rs35705950 is the …

Idiopathic pulmonary fibrosis (IPF) is a complex genetic disease involving both rare and
common genetic variants in its pathogenesis. One prominent common gain-of-function …

Drug-induced interstitial lung disease (ILD) is crucial to detect early to achieve the best
treatment outcome. Optimally, non-invasive imaging biomarkers can be used for early …

Bleomycin-induced pulmonary fibrosis in mice mimics major hallmarks of idiopathic
pulmonary fibrosis. Yet in this model, it spontaneously resolves over time. We studied …

RATIONALE: We have previously found that Muc5b overexpression causes mucociliary
dysfunction and enhances lung fibrosis in SFTPC-Muc5bTg mice exposed to bleomycin …

The airway epithelium serves as the interface between the host and external environment. In
many chronic lung diseases, the airway is the site of substantial remodeling after injury …

Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease characterized by
the relentless deposition of extracellular matrix (ECM), causing lung distortions and …